Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody.
about
Sugar-coated sperm: Unraveling the functions of the mammalian sperm glycocalyxAnti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefitsStructure of UDP complex of UDP-galactose:beta-galactoside-alpha -1,3-galactosyltransferase at 1.53-A resolution reveals a conformational change in the catalytically important C terminusStructural basis of ordered binding of donor and acceptor substrates to the retaining glycosyltransferase, alpha-1,3-galactosyltransferaseCharacteristics of α-Gal epitope, anti-Gal antibody, α1,3 galactosyltransferase and its clinical exploitation (Review)Autoreactivity by design: innate B and T lymphocytesAdult and neonatal anti-Gal response in knock-out mice for alpha1,3galactosyltransferaseLytic anti-alpha-galactosyl antibodies from patients with chronic Chagas' disease recognize novel O-linked oligosaccharides on mucin-like glycosyl-phosphatidylinositol-anchored glycoproteins of Trypanosoma cruziGenetic basis for the lack of N-glycolylneuraminic acid expression in human tissues and its implication to human evolutionThe Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevanceXenotransplantation.Specificity and mechanism of metal ion activation in UDP-galactose:beta -galactoside-alpha -1,3-galactosyltransferase.Chimerism and xenotransplantation. New concepts.Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines.Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alpha-gal epitopesEndotoxemia is associated with altered innate and adaptive immune responses in untreated HIV-1 infected individuals.Hepatic and intestinal transplantation at the University of Pittsburgh.Human immune reactivity against liver sinusoidal endothelial cells from GalTα(1,3)GalT-deficient pigs.Antigen localization and migration in immunity and tolerance.Altered functionality of anti-bacterial antibodies in patients with chronic hepatitis C virus infectionConversion of tumors into autologous vaccines by intratumoral injection of α-Gal glycolipids that induce anti-Gal/α-Gal epitope interaction.Characteristics of protein-carbohydrate interactions as a basis for developing novel carbohydrate-based antirejection therapies.In Situ Conversion of Melanoma Lesions into Autologous Vaccine by Intratumoral Injections of α-gal Glycolipids.A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody.Synthesis of a Liposomal MUC1 Glycopeptide-Based Immunotherapeutic and Evaluation of the Effect of l-Rhamnose Targeting on Cellular Immune ResponsesCellular therapy and bioartificial approaches to liver replacementIntervention of carbohydrate recognition by proteins and nucleic acids.The relation of the level of serum anti-TF, -Tn and -alpha-Gal IgG to survival in gastrointestinal cancer patientsWill xenotransplantation ever be feasible?Complement activation and coagulation in xenotransplantation.Hidden IgG Antibodies to the Tumor-Associated Thomsen-Friedenreich Antigen in Gastric Cancer Patients: Lectin Reactivity, Avidity, and Clinical Relevance.Transgenic pigs designed to express human CD59 and H-transferase to avoid humoral xenograft rejection.Simple radioimmunological assay of anti-alpha-galactosyl antibody (anti-Gal): application to autoimmune thyroid diseases and thyroid-associated ophthalmopathy.Tyrosine phosphorylation following lectin mediated endothelial cell stimulation.Tick-induced allergies: mammalian meat allergy, tick anaphylaxis and their significance.CD55 limits sensitivity to complement-dependent cytolysis triggered by heterologous expression of α-gal xenoantigen in colon tumor cells.An antibody present in normal human serum inhibits the binding of cytokines to their receptors in an in vitro system.Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes.Evolution of immunologic functions of the mammary gland and the postnatal development of immunity.A systems approach to designing next generation vaccines: combining α-galactose modified antigens with nanoparticle platforms.
P2860
Q27001029-74BC7F6E-DC26-4E9E-AFBB-9B1641DA8003Q27021788-C6F9E970-421E-4153-B8E7-585131941332Q27635303-0F07F9B0-C5C8-4B50-81EA-BC5939383474Q27638986-E1F4FA92-5E46-4596-B0AF-4E17C23E709CQ28084522-8B43250F-38C9-44C7-8314-2F8AE80ADCBAQ28208367-E1858C2E-5EFD-4FA3-909F-B24C6DC163B8Q28282784-1D2C22B0-F7B7-44C0-8D03-3733A625D3D5Q28368291-2D77CAD6-25B2-4D99-AD8F-36424066C469Q28650148-F36E0EF6-4FA0-4E25-91FA-E18FE08D810AQ28755302-F3FDACDD-BC5E-4E6B-AEE1-C25E84670C43Q30838629-E5AF1811-EECE-499B-8525-E0AB7A8CC127Q31777391-47AC7ECE-350D-4A95-B7DA-05F4714BF7E6Q33540226-A32671A5-2DD3-4047-ABC2-D522BDC479A4Q33570326-23C1E7D8-35D0-42B9-AA9D-685164A36314Q33837215-64BED02E-6787-46E5-AED0-C14B55D1F1B4Q33952268-591A822C-4497-4EE5-83FF-17E91071152AQ34206468-E80E85A5-C20F-4661-8299-459F11D72BC4Q34213417-5C529FF1-44D0-448C-8B05-FD93C417A2D7Q34239865-28EE29BD-53F1-499E-9981-BA79A21C6EB7Q34764161-A064332A-D02E-48C7-A1CD-FCC2FCF7998DQ35579313-9FD6A5E4-29BC-495B-97F1-1AAA71E1B51AQ36304925-58D9598B-349C-4E50-B8B1-7DBC07ADC777Q36331013-286862B2-36F3-4510-925B-6CA104F78EF6Q36365516-0F3034D8-5EB2-4B95-9266-9B1A53F04663Q36815144-FD54CF10-FC6A-4890-BA93-3370BF81EE71Q36929640-CA0FDF9E-7385-4003-B754-C46362E0819BQ37224944-2D626E1B-0995-4840-86AF-B41505C63FBDQ37246080-05C23A40-618A-4BA2-B931-02B320D6DE7AQ37347546-1C47A0CE-C49A-4C70-8126-C45A98E1E0E5Q37372498-CB60374B-BDAF-40CD-B0D5-79E4E30792EEQ37683571-0B94BF44-A2B2-447D-925B-F185431DC3A9Q38289368-66AF53E7-82DA-4F0E-B031-7BA6222EE2ECQ38289646-3A077A82-156E-4291-8F9A-73028AD572C7Q38330602-3CFAD542-AD6E-47CE-8C69-16565F4B9C33Q38344918-A44697BD-3F2A-41F2-A0DF-B9B8D4C82CFCQ39001370-C8FCB470-C030-4421-8159-FB8C275AA51EQ40927839-7A8D1516-0B94-40DA-82D6-95A4F94B3120Q41495119-7484CD61-5E2A-4126-BBD9-19401C18AE69Q41706705-70F58941-F293-45F9-9D7C-D73C0FA453DCQ41879397-4435D619-33DA-4797-9052-9AD2CEC8A32A
P2860
Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody.
description
1993 nî lūn-bûn
@nan
1993 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Evolution and pathophysiology ...... tosyl IgG (anti-Gal) antibody.
@ast
Evolution and pathophysiology ...... tosyl IgG (anti-Gal) antibody.
@en
Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG
@nl
type
label
Evolution and pathophysiology ...... tosyl IgG (anti-Gal) antibody.
@ast
Evolution and pathophysiology ...... tosyl IgG (anti-Gal) antibody.
@en
Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG
@nl
prefLabel
Evolution and pathophysiology ...... tosyl IgG (anti-Gal) antibody.
@ast
Evolution and pathophysiology ...... tosyl IgG (anti-Gal) antibody.
@en
Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG
@nl
P356
P1476
Evolution and pathophysiology ...... tosyl IgG (anti-Gal) antibody.
@en
P2093
P2888
P304
P356
10.1007/BF00201098
P577
1993-01-01T00:00:00Z
P6179
1002985335